Premium
The long‐term survival of simultaneous pancreas and kidney transplant with basiliximab induction therapy
Author(s) -
Zhang Rubin,
Florman Sandy,
Devidoss Sharmila,
Zarifian April,
Killackey Mary,
Paramesh Anil,
Fonseca Vivian,
Batuman Vecihi,
Hamm L. Lee,
Slakey Douglas
Publication year - 2007
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/j.1399-0012.2007.00692.x
Subject(s) - basiliximab , medicine , tacrolimus , induction therapy , urology , mycophenolic acid , kidney transplantation , kidney , gastroenterology , pancreas , surgery , mycophenolate , transplantation , chemotherapy
Interleukin‐2 receptor (IL2R) antibody has emerged as an attractive induction therapy for organ transplant. However, the long‐term outcome of basiliximab induction in simultaneous pancreas and kidney (SPK) transplant remains speculative. We retrospectively analyzed the long‐term survivals of 91 consecutive SPK recipients with basiliximab as induction, combination of steroid, tacrolimus (TAC) and mycophenolate acid (MFA) – either mycophenolate mofetil (MMF) or sodium mycophenolate (myfortic) as maintenance. At one, three, five, and seven‐yr, the actual patient survival rate were 91.2%, 90.3%, 88.1%, and 88.2%, respectively; kidney graft survivals were 90.1%, 84.7%, 78.6%, and 70.6%, respectively; and pancreas graft survivals were 86.8%, 80.6%, 71.4%, and 58.8% respectively. There was a low incidence of rejection and CMV infection. Basiliximab induction with TAC, MFA, and steroid maintenance therapy can provide excellent long‐term outcome for SPK recipients.